3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
10
Gynecologic
6
Head & Neck
5
Genitourinary
5
Dermatologic
5
Thoracic
4
Breast
4
Other solid neoplasm
2
Sarcoma
1
CNS
1
Conditions
Sarcoma
22
Melanoma
6
Histiocytoma, Malignant Fibrous
6
Gastrointestinal Stromal Tumors
5
Osteosarcoma
4
Neoplasm Metastasis
4
Gliosarcoma
4
Neuroblastoma
3
Hemangiosarcoma
3
Chordoma
3
Bone Neoplasms
3
Wilms Tumor
2
Triple Negative Breast Neoplasms
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Nasopharyngeal Carcinoma
2
Lymphoma
2
Lung Neoplasms
2
Liver Neoplasms
2
Liposarcoma
2
Head and Neck Neoplasms
2
Glioblastoma
2
Endometrial Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Bile Duct Neoplasms
2
Interventions
Cisplatin
5
Carboplatin
5
Cyclophosphamide
4
Bevacizumab
4
130-nm albumin-bound paclitaxel
4
pembrolizumab
3
Oxaliplatin
3
Magnetic Resonance Spectroscopy
3
Leucovorin
3
Irinotecan
3
Gemcitabine
3
Fluorouracil
3
Docetaxel
3
Capecitabine
3
tislelizumab
2
fludarabine
2
Specimen Handling
2
Riluzole
2
Quality of Life
2
Psychiatric Rehabilitation
2
Oncolytic Virotherapy
2
Observation
2
Fluorodeoxyglucose F18
2
Fluorescein
2
Floxuridine
2
Filgrastim
2
Drug Therapy
2
Cetuximab
2
umbralisib
1
trifluridine tipiracil drug combination
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
Ipilimumab
×
Sarcoma
×
Clear all
NCT03752398
2024-07-05
DUET-3
Xencor, Inc.
Phase 1
Completed
198 enrolled